Longevity is, increasingly, a big business. Advances in healthcare technology and AI have prompted both prominent medical professionals and individual investors to imagine how people might live longer, healthier lives. Though still fairly small overall, the longevity industry is expected to nearly triple in size from 2025 to 2035.
Longevity is still very much a niche play for investors, and there are few ways to get involved directly outside of positions in a handful of individual biotech firms. Investors taking a longer view of the industry—or those unsure of how to make a specific bet on one or more single companies, given the nascent nature of the longevity space—might instead opt for an exchange-traded fund (ETF).
